ACB
Price
$3.35
Change
-$0.40 (-10.67%)
Updated
Feb 5, 02:19 PM (EDT)
Capitalization
211.94M
133 days until earnings call
Intraday BUY SELL Signals
SBFM
Price
$1.16
Change
-$0.05 (-4.13%)
Updated
Feb 5, 03:46 PM (EDT)
Capitalization
5.99M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs SBFM

Header iconACB vs SBFM Comparison
Open Charts ACB vs SBFMBanner chart's image
Aurora Cannabis
Price$3.35
Change-$0.40 (-10.67%)
Volume$400
Capitalization211.94M
Sunshine Biopharma
Price$1.16
Change-$0.05 (-4.13%)
Volume$416
Capitalization5.99M
ACB vs SBFM Comparison Chart in %
ACB
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACB vs. SBFM commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ACB: $3.75 vs. SBFM: $1.21)
Brand notoriety: ACB: Notable vs. SBFM: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 161% vs. SBFM: 175%
Market capitalization -- ACB: $211.94M vs. SBFM: $5.99M
ACB [@Pharmaceuticals: Generic] is valued at $211.94M. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $5.99M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, SBFM is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while SBFM’s TA Score has 4 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 5 bearish.
  • SBFM’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SBFM is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -13.19% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was -6.20% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.57%. For the same industry, the average monthly price growth was -1.57%, and the average quarterly price growth was +13.49%.

Reported Earning Dates

ACB is expected to report earnings on Jun 18, 2026.

SBFM is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.57% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($212M) has a higher market cap than SBFM($5.99M). ACB has higher P/E ratio than SBFM: ACB (19.44) vs SBFM (0.23). SBFM YTD gains are higher at: -1.626 vs. ACB (-11.137). SBFM has higher annual earnings (EBITDA): -6.2M vs. ACB (-19.87M). ACB has more cash in the bank: 95.7M vs. SBFM (9.31M). SBFM has less debt than ACB: SBFM (855K) vs ACB (100M). ACB has higher revenues than SBFM: ACB (367M) vs SBFM (37.3M).
ACBSBFMACB / SBFM
Capitalization212M5.99M3,542%
EBITDA-19.87M-6.2M321%
Gain YTD-11.137-1.626685%
P/E Ratio19.440.238,461%
Revenue367M37.3M984%
Total Cash95.7M9.31M1,028%
Total Debt100M855K11,696%
FUNDAMENTALS RATINGS
ACB vs SBFM: Fundamental Ratings
ACB
SBFM
OUTLOOK RATING
1..100
552
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
6183
P/E GROWTH RATING
1..100
9171
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (43) in the null industry is in the same range as ACB (60) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

SBFM's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as SBFM (96) in the null industry. This means that ACB’s stock grew similarly to SBFM’s over the last 12 months.

ACB's Price Growth Rating (61) in the Pharmaceuticals Other industry is in the same range as SBFM (83) in the null industry. This means that ACB’s stock grew similarly to SBFM’s over the last 12 months.

SBFM's P/E Growth Rating (71) in the null industry is in the same range as ACB (91) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBSBFM
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
78%
Bullish Trend 9 days ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTGHF52.103.66
+7.56%
DAIMLER TRUCK HLDG AG
SFRGY3.780.07
+1.75%
Salvatore Ferragamo S.P.A.
VLQCF0.22N/A
N/A
Quantum Graphite Ltd.
XYIGF1.35N/A
N/A
Xinyi Glass Holdings Ltd.
BBOE0.61N/A
N/A
Black Box Entertainment Ltd.

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-7.64%
CGC - ACB
66%
Loosely correlated
-0.85%
SNDL - ACB
65%
Loosely correlated
-1.89%
OGI - ACB
65%
Loosely correlated
-1.27%
TLRY - ACB
63%
Loosely correlated
-2.31%
CRON - ACB
56%
Loosely correlated
+0.39%
More

SBFM and

Correlation & Price change

A.I.dvisor indicates that over the last year, SBFM has been loosely correlated with AQST. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SBFM jumps, then AQST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-1.63%
AQST - SBFM
37%
Loosely correlated
-2.44%
PRGO - SBFM
37%
Loosely correlated
+4.03%
AKBA - SBFM
36%
Loosely correlated
-2.84%
ACB - SBFM
35%
Loosely correlated
-7.64%
SXTC - SBFM
34%
Loosely correlated
-13.02%
More